ATE473744T1 - Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren - Google Patents

Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren

Info

Publication number
ATE473744T1
ATE473744T1 AT05771551T AT05771551T ATE473744T1 AT E473744 T1 ATE473744 T1 AT E473744T1 AT 05771551 T AT05771551 T AT 05771551T AT 05771551 T AT05771551 T AT 05771551T AT E473744 T1 ATE473744 T1 AT E473744T1
Authority
AT
Austria
Prior art keywords
receptor modulators
glucocorticoid receptor
modified pyrimidine
pyrimidine glucocorticoid
modified
Prior art date
Application number
AT05771551T
Other languages
German (de)
English (en)
Inventor
Robin Clark
Nicholas C Ray
Karen Williams
Peter H Crackett
Gwen Hickin
David A Clark
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of ATE473744T1 publication Critical patent/ATE473744T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
AT05771551T 2004-07-02 2005-06-29 Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren ATE473744T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58501804P 2004-07-02 2004-07-02
PCT/US2005/023675 WO2006014394A1 (en) 2004-07-02 2005-06-29 Modified pyrimidine glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
ATE473744T1 true ATE473744T1 (de) 2010-07-15

Family

ID=35311764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771551T ATE473744T1 (de) 2004-07-02 2005-06-29 Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren

Country Status (16)

Country Link
US (2) US7576076B2 (enExample)
EP (1) EP1778236B1 (enExample)
JP (1) JP4958774B2 (enExample)
KR (1) KR101210730B1 (enExample)
AT (1) ATE473744T1 (enExample)
AU (1) AU2005270039B2 (enExample)
CA (1) CA2572544C (enExample)
CY (1) CY1110828T1 (enExample)
DE (1) DE602005022319D1 (enExample)
DK (1) DK1778236T3 (enExample)
ES (1) ES2348667T3 (enExample)
IL (1) IL180508A0 (enExample)
NZ (1) NZ552984A (enExample)
PT (1) PT1778236E (enExample)
WO (1) WO2006014394A1 (enExample)
ZA (1) ZA200700616B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010571A (es) * 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
EP1828192B1 (en) * 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
JPWO2008018592A1 (ja) * 2006-08-11 2010-01-07 大正製薬株式会社 プロスタグランジン誘導体含有外用剤
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
ES2626131T3 (es) 2007-10-17 2017-07-24 Laboratoire Hra Pharma Antagonistas del receptor de glucocorticoides tales como mifepristona para tratar el síndrome de Cushing
GB2477256B (en) * 2008-11-07 2013-12-25 Univ Sheffield Determination of predisposition towards subclinical Cushing's syndrome or incidentaloma
RU2599253C2 (ru) 2011-03-18 2016-10-10 Корсепт Терапьютикс, Инк. Пиримидинциклогексильные модуляторы глюкокортикоидных рецепторов
EP3434274A1 (en) * 2011-03-31 2019-01-30 Pop Test Oncology LLC Prevention of infection
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2016032127A2 (ko) * 2014-08-25 2016-03-03 부산대학교 산학협력단 Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도
KR101686872B1 (ko) * 2014-08-25 2016-12-20 부산대학교 산학협력단 Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
UA127409C2 (uk) 2017-03-31 2023-08-16 Корцепт Терап'Ютікс, Інк. Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки
WO2018226976A1 (en) * 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
MX2020012831A (es) * 2018-06-04 2021-04-28 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoide de pirimidina ciclohexenilo.
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
IL284061B2 (en) 2018-12-19 2025-02-01 Corcept Therapeutics Inc A preparation containing a relaxant
AU2020400061B2 (en) 2019-12-11 2025-02-13 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
EP4603142A3 (en) 2019-12-23 2025-08-27 Crinetics Pharmaceuticals, Inc. Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
US11548856B2 (en) 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
CN115515569A (zh) 2020-05-06 2022-12-23 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂的制剂
AU2021409656B2 (en) 2020-12-21 2025-04-10 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
KR20250102046A (ko) 2022-10-28 2025-07-04 코어셉트 쎄라퓨틱스 인코포레이티드 다주코릴란트를 이용한 근위축성 측삭경화증의 치료

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3011809A1 (de) * 1980-03-27 1981-10-01 Cassella Ag, 6000 Frankfurt Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung
US5008267A (en) 1988-10-29 1991-04-16 Mitsui Toatsu Chemicals, Incorporated Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
JPH06128238A (ja) 1992-10-20 1994-05-10 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体
EP0722732A1 (en) 1995-01-24 1996-07-24 Mitsui Toatsu Chemicals, Inc. Long-acting drug formulation containing pyrimidinedione derivatives
JPH1017555A (ja) 1996-07-02 1998-01-20 Mitsui Petrochem Ind Ltd ６−アミノ−５−メチルウラシル誘導体
ATE303369T1 (de) * 2000-10-30 2005-09-15 Pfizer Prod Inc Glucocorticoid rezeptor modulatoren
GB0029100D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
JP2003017555A (ja) 2001-06-29 2003-01-17 Hitachi Ltd 半導体集積回路装置およびその製造方法
AU2003216591A1 (en) 2002-04-10 2003-10-20 Orichid Chemicals And Pharmaceuticals Limited Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological

Also Published As

Publication number Publication date
PT1778236E (pt) 2010-10-19
US20090275600A1 (en) 2009-11-05
AU2005270039A1 (en) 2006-02-09
US7576076B2 (en) 2009-08-18
ZA200700616B (en) 2008-09-25
KR20070039579A (ko) 2007-04-12
KR101210730B1 (ko) 2012-12-10
JP4958774B2 (ja) 2012-06-20
CA2572544A1 (en) 2006-02-09
CY1110828T1 (el) 2015-06-10
JP2008505117A (ja) 2008-02-21
AU2005270039B2 (en) 2011-09-01
WO2006014394A1 (en) 2006-02-09
ES2348667T3 (es) 2010-12-10
DE602005022319D1 (de) 2010-08-26
EP1778236A1 (en) 2007-05-02
EP1778236B1 (en) 2010-07-14
IL180508A0 (en) 2007-06-03
CA2572544C (en) 2013-02-26
US20060025405A1 (en) 2006-02-02
HK1097768A1 (en) 2007-07-06
NZ552984A (en) 2010-06-25
DK1778236T3 (da) 2010-10-25
US8173664B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
DK1761497T3 (da) Azadecalinglucocorticoidreceptormodulatorer
TNSN07196A1 (en) Potentiators of glutamate receptors
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY1108621T1 (el) Ενωσεις συγχωνευμενου δακτυλιου αζαδεκαλινης ως ρυθμιστες υποδοχεα γλυκοκορτικοειδων
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
NO20074277L (no) Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
NO20073369L (no) Modulatorer av muskarinreseptorer
TW200738649A (en) Calcilytic compounds
EA200601267A1 (ru) Модуляторы рецепторов андрогена
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
TW200716130A (en) Purified form of tanaproget
ATE417816T1 (de) Anilinohexafluoroisopropanol verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1778236

Country of ref document: EP